VAISHALI · Healthcare · Drug Manufacturers - Specialty & Generic
Composite scorecard: 26/100 — Quality 27 · Valuation 40 · Momentum 0
| Share price | ₹8.51 |
| Market cap | ₹101 Cr |
| P/E ratio | 128.7 |
| P/B ratio | 1.5 |
| ROE | 5.8% |
| ROCE | 4.7% |
| Book value | ₹5.30 |
| Year | Sales | Net profit | OPM |
|---|---|---|---|
| 2026 | ₹109 Cr | ₹4 Cr | 3.8% |
| 2025 | ₹98 Cr | ₹1 Cr | 6.0% |
| 2024 | ₹82 Cr | ₹1 Cr | 7.8% |
| 2023 | ₹64 Cr | ₹7 Cr | 14.1% |
| 2022 | ₹72 Cr | ₹4 Cr | 9.1% |
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally. It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, antimalarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic. The company also provides formulations, including antibiotics, antibacteria